Abstract
Twenty six patients (17 females) with β thalassaemia major with a mean (SD) age of 17.4 (8.3) years (range 4–33 years) were studied. Their body surface area (BSA) was 1.12 (0.20) m2. None had congestive heart failure clinically and all were in New York Heart Association (NYHA) functional class I at initial assessment. Monthly blood transfusion was started at a median of 11 months (range 3–96 months), while desferrioxamine was started at a median age of 30 months (range 25–114 months). Post-transfusion haemoglobin was targeted at 14 g/dl (8.7 mmol/l), and echocardiographic studies were performed within one week of transfusion to minimise confounding influence of anaemia. Only one of the patients had undergone splenectomy. Twenty healthy subjects (13 females) aged 10.4 (4.5) years (range 4–15 years), with a BSA of 1.40 (0.23) m2, were recruited as controls. The institutional ethics committee approved the study and parents or subjects themselves gave informed consent.